[go: up one dir, main page]

BRPI0407121B8 - solução farmacêutica estável para prevenir ou reduzir náuseas e vômitos, método de estocagem e de enchimento do recipiente com a dita solução - Google Patents

solução farmacêutica estável para prevenir ou reduzir náuseas e vômitos, método de estocagem e de enchimento do recipiente com a dita solução

Info

Publication number
BRPI0407121B8
BRPI0407121B8 BRPI0407121A BRPI0407121A BRPI0407121B8 BR PI0407121 B8 BRPI0407121 B8 BR PI0407121B8 BR PI0407121 A BRPI0407121 A BR PI0407121A BR PI0407121 A BRPI0407121 A BR PI0407121A BR PI0407121 B8 BRPI0407121 B8 BR PI0407121B8
Authority
BR
Brazil
Prior art keywords
solution
vomiting
filling
container
prevent
Prior art date
Application number
BRPI0407121A
Other languages
English (en)
Inventor
Bonadeo Daniele
Braglia Enrico
Calderari Giorgio
Braglia Ricardo
Cannella Roberta
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32825409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0407121(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of BRPI0407121A publication Critical patent/BRPI0407121A/pt
Publication of BRPI0407121B1 publication Critical patent/BRPI0407121B1/pt
Publication of BRPI0407121B8 publication Critical patent/BRPI0407121B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"solução farmacêutica estável para prevenir ou reduzir náuseas e vômitos, método de estocagem e de enchimento do recipiente com a dita solução". a presente invenção relata para formulações líquidas estável do palonosetron para redução de náuseas e vômitos induzidos pela quimioterapia e radioterapia. as formulações são particularmente usadas nas preparações intravenosas e medicamentos orais líquidos.
BRPI0407121A 2003-01-30 2004-01-30 solução farmacêutica estável para prevenir ou reduzir náuseas e vômitos, método de estocagem e de enchimento do recipiente com a dita solução BRPI0407121B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44435103P 2003-01-30 2003-01-30
PCT/EP2004/000888 WO2004067005A1 (en) 2003-01-30 2004-01-30 Liquid pharmaceutical formulations of palonosetron

Publications (3)

Publication Number Publication Date
BRPI0407121A BRPI0407121A (pt) 2006-01-10
BRPI0407121B1 BRPI0407121B1 (pt) 2018-07-17
BRPI0407121B8 true BRPI0407121B8 (pt) 2021-06-29

Family

ID=32825409

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407121A BRPI0407121B8 (pt) 2003-01-30 2004-01-30 solução farmacêutica estável para prevenir ou reduzir náuseas e vômitos, método de estocagem e de enchimento do recipiente com a dita solução

Country Status (40)

Country Link
US (9) US7947724B2 (pt)
EP (2) EP1601359B1 (pt)
JP (2) JP5461763B2 (pt)
KR (1) KR101113084B1 (pt)
CN (2) CN1758911A (pt)
AP (1) AP2110A (pt)
AR (1) AR042977A1 (pt)
AT (1) ATE410167T1 (pt)
AU (1) AU2004208505C1 (pt)
BR (1) BRPI0407121B8 (pt)
CA (5) CA2573363A1 (pt)
CR (1) CR7921A (pt)
CY (1) CY1108660T1 (pt)
DE (1) DE602004016967D1 (pt)
DK (1) DK1601359T3 (pt)
EA (1) EA014066B1 (pt)
EC (1) ECSP055938A (pt)
ES (1) ES2315635T3 (pt)
GE (1) GEP20084445B (pt)
HR (1) HRP20050676B1 (pt)
IL (1) IL169859A (pt)
IS (1) IS7984A (pt)
JO (1) JO2735B1 (pt)
MA (1) MA27710A1 (pt)
MX (1) MXPA05008028A (pt)
MY (1) MY144036A (pt)
NO (1) NO329500B1 (pt)
NZ (1) NZ541533A (pt)
PA (1) PA8594801A1 (pt)
PE (1) PE20050066A1 (pt)
PL (1) PL378398A1 (pt)
PT (1) PT1601359E (pt)
RS (1) RS20050578A (pt)
SI (1) SI1601359T1 (pt)
TN (1) TNSN05180A1 (pt)
TW (1) TWI342212B (pt)
UA (1) UA90449C2 (pt)
UY (1) UY28175A1 (pt)
WO (1) WO2004067005A1 (pt)
ZA (1) ZA200506917B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
CN100455286C (zh) * 2006-11-21 2009-01-28 深圳海创医药科技发展有限公司 帕洛诺司琼注射液及其制备方法
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
US20120253046A1 (en) 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2361090B1 (en) 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
EP2744497B1 (en) 2011-10-18 2016-04-06 Helsinn Healthcare SA Therapeutic combinations of netupitant and palonosetron
WO2015099381A1 (ko) 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
CN104784107A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种盐酸托烷司琼口服液的制备方法
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
PT3435980T (pt) * 2016-06-06 2020-02-21 Helsinn Healthcare Sa Formulações injetáveis fisiologicamente equilibradas de fosnetupitant
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Novel triple combination formulations for antiemetic therapy
SI3737378T1 (sl) * 2018-01-12 2023-06-30 Orion Corporation Kapljice palonosetrona za oči za zdravljenje ali preprečevanje slabosti in bruhanja
JP7090845B2 (ja) * 2018-08-03 2022-06-27 高田製薬株式会社 パロノセトロン含有液体組成物
JP7438802B2 (ja) * 2020-03-23 2024-02-27 シオノギファーマ株式会社 パロノセトロン含有組成物
TW202428273A (zh) * 2023-01-03 2024-07-16 瑞士商赫爾辛保健公司 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS599539B2 (ja) * 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
DE3650772T2 (de) 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
PL166272B1 (pl) * 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
DK0694545T3 (da) 1991-05-03 2000-09-18 Searle & Co Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3845902B2 (ja) * 1996-07-09 2006-11-15 ソニー株式会社 磁気記録再生装置
ATA156496A (de) 1996-09-03 1997-10-15 Nycomed Austria Gmbh Pharmazeutische zusammensetzung
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
DE19833119A1 (de) 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
ATE229324T1 (de) * 1998-10-27 2002-12-15 Alcon Lab Inc Konservierungsmittel für lokale pharmazeutische zubereitungen enthaltend eine fettsäure/aminosäure enthaltende seife
US6699852B2 (en) * 2000-12-20 2004-03-02 Bristol-Myers Squibb Pharma Company Substituted pyridoindoles as serotonin agonists and antagonists
US7211596B2 (en) 2001-05-11 2007-05-01 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
WO2003100091A1 (en) 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
AU2003302072A1 (en) 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
AU2003303210A1 (en) * 2002-12-19 2004-07-14 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
MXPA05007379A (es) 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Also Published As

Publication number Publication date
CN1758911A (zh) 2006-04-12
KR101113084B1 (ko) 2012-02-15
MXPA05008028A (es) 2006-01-27
MY144036A (en) 2011-07-29
JP2011236242A (ja) 2011-11-24
US20160317440A1 (en) 2016-11-03
PL378398A1 (pl) 2006-04-03
US20110192493A1 (en) 2011-08-11
RS20050578A (sr) 2007-09-21
AP2110A (en) 2010-03-01
CA2573241A1 (en) 2004-08-12
NZ541533A (en) 2008-12-24
EP2008659A1 (en) 2008-12-31
US20060167071A1 (en) 2006-07-27
SI1601359T1 (sl) 2009-04-30
WO2004067005A1 (en) 2004-08-12
CA2573228A1 (en) 2004-08-12
EA200501203A1 (ru) 2006-06-30
JP5461763B2 (ja) 2014-04-02
MA27710A1 (fr) 2006-01-02
PT1601359E (pt) 2008-11-03
US20140039000A1 (en) 2014-02-06
US7947725B2 (en) 2011-05-24
AR042977A1 (es) 2005-07-13
JO2735B1 (en) 2013-09-15
NO20053987L (no) 2005-08-26
US8598218B2 (en) 2013-12-03
KR20050104363A (ko) 2005-11-02
CA2514224A1 (en) 2004-08-12
AP2005003382A0 (en) 2005-09-30
EP1601359A1 (en) 2005-12-07
US8518981B2 (en) 2013-08-27
EP1601359B1 (en) 2008-10-08
GEP20084445B (en) 2008-08-10
ES2315635T3 (es) 2009-04-01
US7960424B2 (en) 2011-06-14
AU2004208505A1 (en) 2004-08-12
HRP20050676B1 (hr) 2013-02-28
ECSP055938A (es) 2006-03-01
AU2004208505A2 (en) 2004-08-12
US20140097114A1 (en) 2014-04-10
JP5551658B2 (ja) 2014-07-16
CR7921A (es) 2006-02-07
TW200418517A (en) 2004-10-01
IL169859A (en) 2014-11-30
CY1108660T1 (el) 2014-04-09
UA90449C2 (ru) 2010-05-11
CN102813621A (zh) 2012-12-12
AU2004208505B2 (en) 2009-09-03
JP2006516583A (ja) 2006-07-06
EA014066B1 (ru) 2010-08-30
ATE410167T1 (de) 2008-10-15
TNSN05180A1 (en) 2007-06-11
US7947724B2 (en) 2011-05-24
NO329500B1 (no) 2010-11-01
DK1601359T3 (da) 2009-01-05
US20060069114A1 (en) 2006-03-30
HRP20050676A2 (en) 2005-10-31
BRPI0407121B1 (pt) 2018-07-17
DE602004016967D1 (de) 2008-11-20
US20130267553A1 (en) 2013-10-10
PA8594801A1 (es) 2004-09-16
US9308266B2 (en) 2016-04-12
HK1076401A1 (en) 2006-01-20
TWI342212B (en) 2011-05-21
PE20050066A1 (es) 2005-04-20
CA2573363A1 (en) 2004-08-12
CA2514224C (en) 2009-11-03
CA2573194A1 (en) 2004-08-12
US9457020B2 (en) 2016-10-04
ZA200506917B (en) 2006-08-30
AU2004208505C1 (en) 2015-10-01
US20160000773A1 (en) 2016-01-07
BRPI0407121A (pt) 2006-01-10
US20060167073A1 (en) 2006-07-27
UY28175A1 (es) 2004-09-30
IS7984A (is) 2005-08-15

Similar Documents

Publication Publication Date Title
BRPI0407121B8 (pt) solução farmacêutica estável para prevenir ou reduzir náuseas e vômitos, método de estocagem e de enchimento do recipiente com a dita solução
MX2023006414A (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
WO2005016264A3 (en) Diamine derivatives of quinone and uses thereof
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
CY1113683T1 (el) Συστημα συσκευασιας για φαρμακευτικες συνθεσεις και kit για ενδοφλεβια χορηγηση
PL373456A1 (en) Pharmaceutical preparations for oral administration, containing ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents
JP2006508977A5 (pt)
ES2099649T3 (es) Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida.
BRPI0606119A2 (pt) preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis
CA2534259A1 (en) Glycyrrhizin high-concentration preparation
BRPI0503734A (pt) composição farmacêutica na forma de solução injetável de morfina pronta para uso e forma de dosagem unitária de morfina para administração epidural ou intratecal
AU2004281520B2 (en) Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
Lee et al. Effects of cyclosporin A and tacrolimus on the cross-presentation capability of dendritic cells
TH71263A (th) สูตรผสมทางเภสัชกรรมชนิดเหลวของพาโลนอเซทรอน
RO122835B1 (ro) Utilizarea dietilaminei ca analgezic în preparate farmaceutice
File Jr Snapshots From 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC (Chicago, September 2011)
PL349176A1 (en) Vial for drugs to be repeatedly administered in the form of injections
TH69073A (th) สูตรผสมที่เสถียรสำหรับใช้เฉพาะที่ซึ่งมีคีโตโพรเฟน
WO2004108061A3 (en) Stable injectable pharmaceutical composition of thiopental; method for stabilizing aqueous solutions of thiopental and, use of thiopental for producing a medicament
WO2007062262A3 (en) Gelatinous medicament formulation and method of administration
TH145992A (th) สูตรของสารภูมิต้านทานในมนุษย์สำหรับการบำบัดความผิดปกติที่เกี่ยวเนื่องกับ thf-(อัลฟา)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/4747, 9/08

Ipc: A61K 31/4747 (2011.01), A61K 9/08 (2011.01), A61P

Free format text: PARA: INT. CL. A61K 31/4747, 9/08; A61P 1/08

Ipc: A61K 31/4747 (2011.01), A61K 9/08 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTES DA NULIDADE: 1O)ACHE LABORATORIOS FARMACEUTICOS S.A. - PETICAO NO870190005033 DE 16/01/2019; 2O)CIPLA LIMITED - PETICAO NO870190005397 DE 17/01/2019.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2480 DE 17/07/2018 QUANTO AO APOSTILAMENTO DO QUADRO REIVINDICATORIO.O QUADRO REIVINDICATORIO DEVERA SER LIDO DA SEGUINTE FORMA: REIVINDICACOES1. SOLUCAO FARMACEUTICA ESTAVEL INTRAVENOSA PARA PREVENIR OU REDUZIR NAUSEAS E VOMITOS, CARACTERIZADO PELO FATO DE QUE COMPREENDE: A) 0,03 MG/ML A 0,2 MG/ML DE PALONOSETRON OU SAL FARMACEUTICAMENTE ACEITAVEL DESTE, TAMPONADO A UM PH DE 4,0 A 6,0; E B) UM TRANSPORTADOR FARMACEUTICAMENTE ACEITAVEL, AQUOSO, ESTERIL QUE COMPREENDE DE 10,0A 80,0 MG/ML DE MANITOL E DE 0,005 MG/ML A 1,0 MG/ML DE EDTA. 2. SOLUCAO DE ACORDO COM A REIVINDICACAO 1, CARACTERIZADO PELO FATO DE QUE O PALONOSETRON OU SAL FARMACEUTICAMENTE ACEITAVEL DESTE ESTA NUMA CONCENTRA

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2812 DE 26-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.